Biotech Values

[DewDiligence]

Re: Squalamine may have just gained a year relative to Lucentis:

To clarify #856 and eliminate a possible misunderstanding: "two-year follow-up” means actual treatment rather than just observation. I.e., patients in each of the two phase-3 Lucentis trials will receive a needle in the eye each month for up to 24 months (ouch).